Based on a previous report on transport processes, the expression of MRD1 and breast cancer resistance protein (BCRP) transporter is known to be markedly elevated in lenvatinib-resistant HCC cells, and the activation of EGFR, MEK/ERK, and PI3K/AKT signaling is associated with the acquisition of drug resistance [216]. The gene discussed is MAP2K7; the disease is hepatocellular carcinoma.